Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Seralutinib: efectos antifibróticos significativos y evidencia de modelos derivados de pacientes

Tuesday, March 10, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the significant antifibrotic effects of Seralutinib, highlighting evidence derived from patient models. This suggests a promising potential for the drug in treating conditions associated with fibrosis. The findings may have implications for patients suffering from pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Price reaction · baseline $0.5553 (2026-03-09 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close
-8.7%
day 1
-11.7%
day 3 · peak
-21.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Significant antifibrotic effects of Seralutinib reported.
  • Evidence derived from patient models supports its efficacy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Seralutinib: efectos antifibróticos significativos y evidencia de modelos derivados de pacientes
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is Seralutinib?

Seralutinib is a drug being studied for its antifibrotic effects.

What conditions does Seralutinib target?

It targets pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

What evidence supports Seralutinib's efficacy?

Evidence from patient-derived models indicates significant antifibrotic effects.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib antifibrotic PAH PH-ILD patient models
Last updated: Mar 10, 2026

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →